Medical Literature Monitoring in Pharmacovigilance

Scientific and medical literature is a regulated source of pharmacovigilance information because published reports may contain suspected adverse reactions, new information about known risks, or observations relevant to the benefit-risk balance of a medicinal product. Literature monitoring therefore sits at the interface between case collection, signal management and aggregate safety evaluation.

In the European Economic Area, the European Medicines Agency (EMA) also operates a central Medical Literature Monitoring (MLM) service for selected active substances. The service reduces duplicate screening and duplicate reporting, but it does not abolish the marketing-authorisation holder's wider responsibility to monitor relevant literature.

Regulatory Framework

Article 107 of Directive 2001/83/EC and the wider EU pharmacovigilance framework require marketing-authorisation holders to collect and report suspected adverse reactions from relevant sources. GVP Module VI provides detailed guidance on management and submission of individual case safety reports (ICSRs), including cases originating from scientific and medical literature.

EMA's MLM service is provided under Article 27 of Regulation (EC) No 726/2004. For active substances and literature sources covered by the service, EMA monitors the literature, identifies reportable suspected adverse reactions, creates ICSRs and enters them into EudraVigilance.

The regulatory model is therefore divided:

1. MAHs ordinarily monitor relevant scientific and medical literature for their medicines.
2. EMA centrally monitors specified literature for specified active substances through MLM.
3. For the literature EMA monitors under MLM, MAHs are not required to duplicate that monitoring or submit the same suspected adverse reactions to EudraVigilance.
4. MAHs retain responsibility for literature outside the EMA service and for using literature-derived information in their wider pharmacovigilance system.

Why Literature Matters in Pharmacovigilance

Published literature can contribute information that is absent or incomplete in spontaneous reports received directly by a company. Important sources include case reports, case series, clinical and observational studies, pharmacoepidemiological analyses, conference material and specialist publications.

Literature can provide:

• a new suspected adverse reaction;
• a clinically detailed description of an already known reaction;
• information on risk factors or susceptible populations;
• exposure or epidemiological context;
• mechanistic evidence;
• information on medication error, misuse, interactions or special populations; and
• evidence that strengthens or weakens a signal.

The literature-search objective therefore depends on the pharmacovigilance purpose. A search designed to identify reportable ICSRs is not identical to a broad literature review for a PBRER, signal assessment or emerging safety issue.

What EMA's MLM Service Does

EMA's service monitors selected active substances that are associated with many marketing authorisations and multiple MAHs in the EEA. The service aims to reduce duplicate effort and duplicate case creation and to improve consistency of literature-derived ICSRs.

EMA publishes the substances and literature sources covered by the service. Since 1 April 2024, the service has also included MEDLINE alongside the existing EMBASE-based coverage, allowing potentially relevant articles to become available sooner.

For covered material, EMA:

• screens the designated literature;
• assesses publications for suspected adverse reaction cases;
• creates ICSRs where applicable;
• enters those cases into EudraVigilance; and
• makes the resulting cases available to MAHs.

MLM Does Not Replace Literature Monitoring

The most important operational distinction is coverage.

An MAH should know whether an active substance is included in the EMA MLM service and which literature sources are covered. The company then needs to ensure that its own literature-monitoring strategy addresses what remains outside that coverage.

Residual responsibilities can include:

• literature not monitored by EMA;
• local journals or sources relevant to particular products or markets;
• specialist literature that is not adequately captured by the central service;
• literature needed for purposes beyond ICSR identification, such as signal assessment, PSUR/PBRER preparation or emerging safety issue evaluation; and
• handling of MLM-derived ICSRs within the company's own safety and signal processes.

There is no universal regulatory requirement to review the EMA coverage on a fixed quarterly schedule. The process should instead ensure that changes to the EMA service, product portfolio or relevant literature sources are recognised and incorporated in a timely manner.

Selecting Literature Sources

GVP Module VI explains that the MAH should identify the most relevant sources of published literature for each product. Well-known bibliographic databases may cover a large proportion of the medical literature, but specialist journals, local publications or other sources may contain important information that broader databases do not capture adequately.

The search strategy should therefore be justified by the medicinal product, active substance, therapeutic area and the pharmacovigilance purpose.

A useful literature-monitoring design distinguishes:

The search strategy should remain scientifically defensible rather than simply reproduce a standard corporate list.

From Publication to ICSR

A publication becomes relevant for ICSR processing when it contains enough information to meet the applicable case criteria. The publication itself is the source document; the pharmacovigilance task is to determine whether the article describes one or more identifiable patients, a suspected medicinal product and a suspected adverse reaction, and whether the report is otherwise valid for processing.

Literature-derived cases can be more complex than spontaneous reports because one article may describe multiple patients, aggregate data or a mixture of individual and group-level information. The case-processing approach should preserve the scientific context while avoiding unsupported assumptions about individual patients.

Duplicate management

Literature reports can easily generate duplicates because the same patient may be described in more than one publication or may already exist in EudraVigilance from another source. GVP Module VI and its duplicate-management guidance therefore make duplicate detection an important part of case handling.

Where EMA has created an MLM case, the MAH should avoid creating a duplicate EudraVigilance submission merely because the publication also appears in the company's own surveillance. Internal safety databases may still need to incorporate the case according to the company's pharmacovigilance model and obligations outside the EEA.

Follow-up

Where additional clinically relevant information could materially improve the case, follow-up may be considered in accordance with GVP Module VI and the company's case-management process. The feasibility of follow-up from the literature depends on the publication, the reporter contact details, data-protection considerations and whether the information is already available.

Handling EMA MLM Cases

EMA makes MLM-derived cases available to MAHs so that they can be incorporated into their own safety systems and used for obligations outside the EEA where applicable.

The precise technical workflow depends on the MAH's safety database, EudraVigilance access model and internal process. A robust process should nevertheless answer several questions:

• How are relevant MLM cases identified for the company's products?
• How are duplicates detected against existing company cases?
• How is the EudraVigilance case identifier preserved?
• How are cases incorporated into the internal safety database where required?
• How are cases used for signal detection and aggregate reporting?
• How are corrections or important follow-up handled?

EU guidance does not prescribe one universal weekly download frequency or one mandatory internal screening log. Those can be sensible operational controls, but they should be designed around the company's systems and responsibilities rather than presented as legal requirements.

Relationship With Signal Management

Literature monitoring does more than generate ICSRs. Publications can create or materially influence signals.

A case report may describe an unusual phenotype, positive rechallenge or biologically compelling temporal relationship. An epidemiological paper may provide a risk estimate. A mechanistic study may strengthen causal plausibility. A systematic review may reveal consistency across several data sources.

Signal management should therefore integrate literature at two levels:

1. case-level information, where a publication contributes one or more ICSRs; and
2. non-case evidence, where the publication informs the scientific evaluation even if it does not itself generate an ICSR.

This distinction matters because an organisation that monitors literature only for valid cases can miss evidence that changes the interpretation of a signal or benefit-risk balance.

Relationship With Aggregate Reports and RMPs

PBRERs/PSURs, DSURs and risk-management evaluations also depend on literature evidence. The search strategy for these purposes may be broader than routine ICSR surveillance because the objective is not simply to find individual cases.

Relevant publications may affect:

• signal evaluation;
• characterisation of identified or potential risks;
• exposure and epidemiology;
• effectiveness of risk-minimisation measures;
• benefit evaluation; and
• the integrated benefit-risk assessment.

The literature-monitoring system should therefore avoid creating isolated silos in which case-processing searches, signal searches and aggregate-report searches cannot be reconciled.

Outsourcing Literature Monitoring

Literature surveillance is frequently outsourced to specialist vendors, but responsibility remains with the MAH.

A pharmacovigilance agreement should make clear which substances, products, databases, journals, languages and outputs fall within the vendor's scope, how urgent information is escalated, how missed articles are handled, how search strategies are changed and how records are retained.

Oversight should then demonstrate that the service is actually working. Depending on risk and complexity, this can include review of search outputs, reconciliation, quality checks, metrics, deviations, periodic governance and audit.

There is no single mandatory vendor KPI set or audit interval. The controls should be proportionate to the risk of missing pharmacovigilance information.

QPPV Oversight

The QPPV does not need to perform literature searches personally. The regulatory concern is whether the pharmacovigilance system reliably captures and uses relevant literature and whether significant failures are visible to the QPPV.

QPPV oversight may therefore include awareness of:

• the literature-monitoring model and major outsourced components;
• significant changes in MLM coverage or search strategy;
• serious compliance deviations;
• important missed cases or late reporting;
• major vendor deficiencies; and
• literature findings that materially affect signals or benefit-risk.

A requirement for the QPPV to sign every MLM coverage assessment or routine screening record is not established in EU guidance.

Quality Controls

Quality controls should be designed around likely failure modes.

Examples include:

• testing whether search terms retrieve known relevant publications;
• checking whether products and active substances are mapped correctly;
• reconciling search results with case records;
• reviewing missed-literature deviations;
• monitoring whether important articles are triaged promptly;
• checking duplicate handling; and
• ensuring relevant non-case publications reach signal and aggregate-report processes.

The control should test the real risk. A metric showing “100% searches completed” is weak if the search strategy itself cannot retrieve important literature.

Potential Failure Modes

The following are illustrative failure modes, not published inspection findings.

Inspection Considerations

A pharmacovigilance inspector may examine whether the literature-monitoring system is capable of identifying relevant safety information and whether responsibilities are clearly understood.

Potential inspection questions include:

• How does the MAH determine which literature it must monitor itself?
• How is EMA MLM coverage identified and kept current?
• Which residual databases, journals, languages or local sources are searched?
• How are search strategies developed and changed?
• How are publications assessed for valid ICSRs?
• How are EMA MLM cases incorporated without duplication?
• How does literature information reach signal management and aggregate reporting?
• How are outsourced literature activities controlled?
• What happens when a relevant publication is missed or processed late?
• Can the QPPV obtain information about significant literature-surveillance failures?

The inspection focus is therefore coverage, scientific adequacy, traceability and system integration, not whether a company uses a particular spreadsheet or fixed review interval.

Practical Review Checklist

This checklist is recommended operational practice, not an EMA template.

1. Are all marketed and authorised products mapped to their active substances?
2. Is current EMA MLM coverage understood for those substances?
3. Are residual literature sources justified by product and therapeutic context?
4. Do search terms account for substance names, relevant synonyms and product-specific terminology?
5. Can the search retrieve known relevant publications?
6. Are valid literature ICSRs processed according to GVP Module VI?
7. Are duplicates, including EMA-generated MLM cases, managed appropriately?
8. Do important non-case publications feed signal and benefit-risk processes?
9. Are responsibilities with literature vendors unambiguous?
10. Are missed-publication or late-processing deviations investigated for system impact?
11. Are significant compliance or safety issues escalated appropriately?
12. Can the organisation reconstruct why a publication was included, excluded or handled in a particular way?

Key Takeaways

Medical literature is both a source of ICSRs and a broader source of scientific evidence for pharmacovigilance.

EMA's MLM service centrally monitors specified literature for selected active substances and enters qualifying suspected adverse reaction reports into EudraVigilance. For that covered literature, MAHs do not need to duplicate the monitoring or EV submission. The service does not remove wider literature-monitoring responsibilities.

A sound MAH process therefore begins with coverage: understand what EMA monitors, identify residual sources, process literature-derived cases correctly, avoid duplicates and ensure that scientific publications also reach signal management and aggregate safety evaluation.

Operational controls such as search-review frequencies, download schedules, trackers and QPPV approvals should be proportionate to the company's system. They should not be presented as universal EU requirements.

References

1. European Medicines Agency. Medical literature monitoring. EMA pharmacovigilance webpage describing substances and literature covered, MAH monitoring/reporting requirements and MLM business processes. Current page accessed 7 September 2026.
2. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VI — Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev. 2). EMA/873138/2011 Rev. 2.
3. European Medicines Agency. GVP Module VI Appendix 2 — Detailed guidance on the monitoring of scientific and medical literature.
4. European Medicines Agency. GVP Module IX — Signal management and current EMA signal-management implementation material.
5. European Union. Regulation (EC) No 726/2004, including Article 27 concerning monitoring of selected medical literature by EMA.
6. European Union. Directive 2001/83/EC, as amended.
7. European Union. Commission Implementing Regulation (EU) No 520/2012, consolidated version current at 12 February 2026.

Regulatory Note

As of 7 September 2026, EMA states that MAHs are usually responsible for monitoring medical literature for their medicines, but they are not required to monitor or report suspected adverse reactions from literature that EMA monitors for active substances covered by the MLM service. EMA expanded the service to include MEDLINE from 1 April 2024. GVP modules are undergoing planned updates following Commission Implementing Regulation (EU) 2025/1466, so current EMA guidance should be checked before implementing or revising a live literature-monitoring procedure.